-
公开(公告)号：WO2021110764A1
公开(公告)日：2021-06-10
申请号：PCT/EP2020/084309
申请日：2020-12-02
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： KLEIN, Florian , GRÜLL, Henning , SCHOMMERS, Philipp Frederik
IPC: C07K16/10 , A61P31/18 , A61K39/395
Abstract: The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.
-
公开(公告)号：WO2020178332A1
公开(公告)日：2020-09-10
申请号：PCT/EP2020/055687
申请日：2020-03-04
Applicant: UNIVERSITÄT ZU KÖLN
Abstract: The invention relates to a device for the transplantation of a Descemet's membrane-endothelium graft (5), comprising a longitudinal tube (1), the tube (1) having an inner cavity (2), an inlet opening (3) at its proximal end (PE) through which it is possible to introduce the graft (5) into the cavity (2), and an outlet opening (4) at its distal end (DE) through which it is possible to eject the graft (5) from the cavity (2), particularly into the anterior eye chamber of a patient, a guiding element (6) situated in the cavity (2) of the tube (1) extending from the proximal end area of the tube (1) or device towards the distal end area of the tube (1) or device and having an increasing cross section at least along a part of its extension, particularly by increasing the width of the guiding element (6) more than the height of the guiding element (6), wherein the guiding element (6) extending beyond the outlet opening (4) of the tube into the exterior environment of the tube (1), and having the distal end (6b) of the guiding element (6) being positioned outside of the tube (1) in front of the outlet opening (4) of the tube (1).
-
公开(公告)号：WO2020115291A1
公开(公告)日：2020-06-11
申请号：PCT/EP2019/084015
申请日：2019-12-06
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： VON BRANDENSTEIN, Melanie , KÖDITZ, Barbara , FRIES, Jochen , FUNKE, Timo , SALEM, Johannes
Abstract: The present invention relates to a method for determining the fertility of spermatozoa comprising detecting mitogen-activated protein kinase 14 iso form 3 (Mxi-2).The method may be a method for determining the fertility of spermatozoa contained in a sample S, said method comprising detecting the total content of the Mxi-2 in the sample S. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.
-
公开(公告)号：WO2019063747A1
公开(公告)日：2019-04-04
申请号：PCT/EP2018/076377
申请日：2018-09-28
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： BÜNING, Hildegard , HUBER, Anke , PERABO, Luca
CPC classification number: C12N7/00 , C12N15/86 , C12N2750/14122 , C12N2750/14142 , C12N2750/14143 , C12N2750/14145
Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.g. defined herein is disclosed. Further, a method for the modification of a mutated AAV particle is disclosed allowing a specific modification of the same including an embodiment using a reagent addressing the cysteine residues for binding reaction such as a thioether binding.
-
公开(公告)号：WO2019011941A1
公开(公告)日：2019-01-17
申请号：PCT/EP2018/068713
申请日：2018-07-10
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： VON BRANDENSTEIN, Melanie , FRIES, Jochen
Abstract: The present invention relates to a method for detecting malignant kidney cancer in an individual, said method conducted in vitro comprising the steps of providing a body fluid sample, in particular a urine sample, obtained from the individual, and determining one or more biomarker levels selected from the group consisting of the Mxi-2 level, the Vim3 level, the MAPKp38 level and the Atg7 level in the sample. Further, the present invention refers to a kit and a dipstick for use in such method.
-
Patent Agency Ranking6.发明申请
公开(公告)号：WO2018215563A1
公开(公告)日：2018-11-29
申请号：PCT/EP2018/063562
申请日：2018-05-23
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： WIRTH, Brunhilde , JANZEN, Eva , MENDOZA-FERREIRA, Natalia , HOSSEINIBARKOOIE, Seyyedmohsen
IPC: C12N15/113 , A61K31/7088
CPC classification number: C12N15/113 , A61K31/713 , C12N2310/11
Abstract: The invention relates to an inhibitor of Calcineurin B Homologous Protein 1 (CHP1) for use in a method for the treatment or prevention of a patient suffering from or being at risk of developing a disorder associated with a pathological calcium homeostasis, impaired vesicular trafficking and/or disturbed neuronal and/orneuromuscular synaptic function.
-
公开(公告)号：WO2018001558A1
公开(公告)日：2018-01-04
申请号：PCT/EP2017/000748
申请日：2017-06-27
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： BACHMANN, Björn , SIEBELMANN, Sebastian , CURSIEFEN, Claus
IPC: A61F2/14
Abstract: The invention relates to a device for the transplantation of a Descemet's membrane (2), comprising a longitudinal tube (1) having an inner cavity, an inlet opening (8) through which it is possible to introduce the Descemet's membrane (2) into the device, and an outlet opening (6) through which it is possible to eject the Descemet's membrane (2) from the device, especially into the anterior eye chamber of a patient, wherein the tube has, at least in the region of the outlet opening (6), a separation element (4) which protrudes from the inner wall region of the tube into the cavity, especially a first separation element (4), said separation element dividing the cavity at least regionally, in particular dividing it in a region close to the separation element (4).
Abstract translation: 本发明涉及用于移植德斯密膜（2）的装置，该装置包括具有内腔的纵向管（1），可以引入其中的入口（8） Descemet的膜（2）进入该装置，以及出口开口（6），通过该出口开口可以将Descemet膜（2）从装置中喷射到患者的前眼室中，其中该管具有 至少在出口开口（6）的区域内具有从管的内壁区域突出到腔内的分离元件（4），特别是第一分离元件（4），所述分离元件至少区域地 特别是将其分成靠近分离元件（4）的区域。
-
公开(公告)号：WO2016092069A1
公开(公告)日：2016-06-16
申请号：PCT/EP2015/079410
申请日：2015-12-11
Applicant: FORSCHUNGSVERBUND BERLIN E.V. , UNIVERSITÄT ZU KÖLN
Inventor： KÜHNE, Ronald , SCHMALZ, Hans-Günther , MÜLLER, Matthias , REUTER, Cedric , SOICKE, Arne , OPITZ, Robert , BARONE, Matthias , OSCHKINAT, Hartmut
CPC classification number: C07K7/06 , A61K38/00 , C07D519/00
Abstract: Die vorliegende Erfindung betrifft chemische Verbindungen, die insbesondere als Struktur-Mimetika prolinreicher Peptide eingesetzt werden können. Die Verbindungen der vorliegenden Erfindung sind in der Lage ena/VASP-EVH1-vermittelte Protein-Protein-Wechselwirkungen selektiv zu hemmen. Die Erfindung betrifft weiterhin die Verwendung dieser Verbindungen als pharmazeutische Wirkstoffe sowie die Verwendung der pharmazeutischen Wirkstoffe zur Behandlung von Tumorerkrankungen. Die chemischen Verbindungen der vorliegenden Erfindung können die Chemotaxis und Motilität invasiver Tumorzellen stark hemmen und somit in der Behandlung und/oder Prävention von Tumormetastasen eingesetzt werden.
Abstract translation: 本发明涉及一种可以特别地用作富含脯氨酸的肽的模拟物结构的化合物。 本发明的化合物能够在ENA / VASP EVH1介导蛋白质 - 蛋白质相互作用，以抑制选择性。 本发明还涉及使用这些化合物作为药物活性成分和用于肿瘤疾病的治疗中使用的药剂的。 本发明的化学化合物可以抑制大量侵入性肿瘤细胞的趋化作用和运动性，因此在治疗和/或预防肿瘤转移的使用。
-
公开(公告)号：WO2015044177A1
公开(公告)日：2015-04-02
申请号：PCT/EP2014/070328
申请日：2014-09-24
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： BERKESSEL, Albrecht , KRÜGER, Mark , KREUZER, Karl-Anton , POLL-WOLBECK, Simon
IPC: C07C203/04 , C07C69/76 , C07C309/76 , C07C247/10 , C07F7/08 , A61K31/621 , A61K31/695 , A61P35/00 , A61P35/02
CPC classification number: C07C203/04 , A61K31/215 , A61K31/235 , A61K31/24 , A61K31/621 , C07C69/75 , C07C69/76 , C07C69/78 , C07C69/86 , C07C247/10 , C07C309/76 , C07C2601/14 , C07F7/0818 , C07F7/1852
Abstract: The present invention refers to compounds of formula: (formula A), wherein R 1 is selected from (formula I), (formula II), (formula (III), (formula IV), (formula V), or (formula B), and wherein R 2 , R 3 , R 4 and R 5 are as defined in the claims and X is OTBS, hydroxy, formyloxy, acetoxy, nitrooxy, nitrooxymethyl, or a halogen; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neoplastic or proliferative disorders, a pharmaceutical composition comprising such a compound and a method preparing this compound.
Abstract translation: 本发明涉及下式的化合物（式A），其中R 1选自（式I），（式II），（式（III），（Ⅳ），（式Ⅴ）或（式B） ，其中R2，R3，R4和R5如权利要求中所定义，X是OTBS，羟基，甲酰氧基，乙酰氧基，硝基氧基，硝基氧基甲基或卤素;及其药学上可接受的盐，其可用于治疗肿瘤或 增殖性疾病，包含这种化合物的药物组合物和制备该化合物的方法。
-
公开(公告)号：WO2015018918A1
公开(公告)日：2015-02-12
申请号：PCT/EP2014/067043
申请日：2014-08-07
Applicant: UNIVERSITÄT ZU KÖLN
Inventor： FERNANDEZ-CUESTA, Lynnette , GEORGE, Julie , PLENKER, Dennis , THOMAS, Roman
CPC classification number: C12Q1/6886 , C07K14/4756 , C07K14/70596 , C07K2319/00 , C12Q2600/118 , C12Q2600/158
Abstract: The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.
Abstract translation: 本发明涉及包含NRG1和另外的融合配偶体（如CD74）的新型融合基因。 本发明提供了这些融合基因在诊断以及癌症的医学干预中的用途。
-
-
-
-
-
-
-
-
-
Search Results
102
records
(took 0.032 seconds)
